S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:CLSN

Celsion Competitors

$1.71
-0.14 (-7.57 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.41
Now: $1.71
$1.80
50-Day Range
$0.87
MA: $1.76
$2.81
52-Week Range
$0.43
Now: $1.71
$6.50
Volume8.80 million shs
Average Volume26.16 million shs
Market Capitalization$63.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.42

Competitors

Celsion (NASDAQ:CLSN) Vs. LCI, OVID, TCDA, XERS, AVEO, and TYME

Should you be buying CLSN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Celsion, including Lannett (LCI), Ovid Therapeutics (OVID), Tricida (TCDA), Xeris Pharmaceuticals (XERS), AVEO Pharmaceuticals (AVEO), and Tyme Technologies (TYME).

Celsion (NASDAQ:CLSN) and Lannett (NYSE:LCI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Celsion and Lannett, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celsion02002.00
Lannett03002.00

Celsion presently has a consensus target price of $4.00, suggesting a potential upside of 133.92%. Lannett has a consensus target price of $8.50, suggesting a potential upside of 37.76%. Given Celsion's higher probable upside, equities analysts clearly believe Celsion is more favorable than Lannett.

Institutional and Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 86.1% of Lannett shares are owned by institutional investors. 20.5% of Celsion shares are owned by company insiders. Comparatively, 13.6% of Lannett shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Celsion has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Lannett has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares Celsion and Lannett's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celsion-4,315.00%-104.32%-47.65%
Lannett-5.09%12.62%3.39%

Valuation & Earnings

This table compares Celsion and Lannett's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celsion$500,000.00127.97$-16,850,000.00($0.91)-1.88
Lannett$545.74 million0.47$-33,370,000.00$1.075.77

Celsion has higher earnings, but lower revenue than Lannett. Celsion is trading at a lower price-to-earnings ratio than Lannett, indicating that it is currently the more affordable of the two stocks.

Celsion (NASDAQ:CLSN) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Celsion and Ovid Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celsion02002.00
Ovid Therapeutics05502.50

Celsion presently has a consensus target price of $4.00, suggesting a potential upside of 133.92%. Ovid Therapeutics has a consensus target price of $11.6250, suggesting a potential upside of 192.82%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Celsion.

Institutional and Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 39.6% of Ovid Therapeutics shares are owned by institutional investors. 20.5% of Celsion shares are owned by company insiders. Comparatively, 29.8% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Celsion has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.

Profitability

This table compares Celsion and Ovid Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celsion-4,315.00%-104.32%-47.65%
Ovid TherapeuticsN/A-140.96%-108.72%

Valuation & Earnings

This table compares Celsion and Ovid Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celsion$500,000.00127.97$-16,850,000.00($0.91)-1.88
Ovid TherapeuticsN/AN/A$-60,460,000.00($1.54)-2.58

Celsion has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Celsion, indicating that it is currently the more affordable of the two stocks.

Summary

Celsion beats Ovid Therapeutics on 7 of the 13 factors compared between the two stocks.

Celsion (NASDAQ:CLSN) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Celsion and Tricida, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celsion02002.00
Tricida11202.25

Celsion presently has a consensus target price of $4.00, suggesting a potential upside of 133.92%. Tricida has a consensus target price of $19.50, suggesting a potential upside of 311.39%. Given Tricida's stronger consensus rating and higher probable upside, analysts clearly believe Tricida is more favorable than Celsion.

Institutional and Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 70.5% of Tricida shares are owned by institutional investors. 20.5% of Celsion shares are owned by company insiders. Comparatively, 70.4% of Tricida shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Celsion has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Tricida has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Profitability

This table compares Celsion and Tricida's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celsion-4,315.00%-104.32%-47.65%
TricidaN/A-125.57%-69.25%

Valuation & Earnings

This table compares Celsion and Tricida's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celsion$500,000.00127.97$-16,850,000.00($0.91)-1.88
TricidaN/AN/A$-176,810,000.00($3.72)-1.27

Celsion has higher revenue and earnings than Tricida. Celsion is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Summary

Tricida beats Celsion on 7 of the 13 factors compared between the two stocks.

Celsion (NASDAQ:CLSN) and Xeris Pharmaceuticals (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Celsion and Xeris Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celsion02002.00
Xeris Pharmaceuticals02102.33

Celsion presently has a consensus target price of $4.00, suggesting a potential upside of 133.92%. Xeris Pharmaceuticals has a consensus target price of $13.00, suggesting a potential upside of 168.60%. Given Xeris Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xeris Pharmaceuticals is more favorable than Celsion.

Institutional and Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 69.3% of Xeris Pharmaceuticals shares are owned by institutional investors. 20.5% of Celsion shares are owned by company insiders. Comparatively, 6.1% of Xeris Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Celsion has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Xeris Pharmaceuticals has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Profitability

This table compares Celsion and Xeris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celsion-4,315.00%-104.32%-47.65%
Xeris Pharmaceuticals-2,037.97%-435.27%-91.81%

Valuation & Earnings

This table compares Celsion and Xeris Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celsion$500,000.00127.97$-16,850,000.00($0.91)-1.88
Xeris Pharmaceuticals$2.72 million87.15$-125,580,000.00($4.81)-1.01

Celsion has higher earnings, but lower revenue than Xeris Pharmaceuticals. Celsion is trading at a lower price-to-earnings ratio than Xeris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Celsion (NASDAQ:CLSN) and AVEO Pharmaceuticals (NASDAQ:AVEO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Celsion and AVEO Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celsion02002.00
AVEO Pharmaceuticals00503.00

Celsion presently has a consensus target price of $4.00, suggesting a potential upside of 133.92%. AVEO Pharmaceuticals has a consensus target price of $16.20, suggesting a potential upside of 98.04%. Given Celsion's higher probable upside, equities analysts clearly believe Celsion is more favorable than AVEO Pharmaceuticals.

Institutional and Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 33.7% of AVEO Pharmaceuticals shares are owned by institutional investors. 20.5% of Celsion shares are owned by company insiders. Comparatively, 4.5% of AVEO Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Celsion has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Profitability

This table compares Celsion and AVEO Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celsion-4,315.00%-104.32%-47.65%
AVEO Pharmaceuticals-483.99%-103.66%-48.01%

Valuation & Earnings

This table compares Celsion and AVEO Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celsion$500,000.00127.97$-16,850,000.00($0.91)-1.88
AVEO Pharmaceuticals$28.80 million8.18$9.39 million$0.6113.41

AVEO Pharmaceuticals has higher revenue and earnings than Celsion. Celsion is trading at a lower price-to-earnings ratio than AVEO Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

AVEO Pharmaceuticals beats Celsion on 8 of the 14 factors compared between the two stocks.

Celsion (NASDAQ:CLSN) and Tyme Technologies (NASDAQ:TYME) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Valuation & Earnings

This table compares Celsion and Tyme Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celsion$500,000.00127.97$-16,850,000.00($0.91)-1.88
Tyme TechnologiesN/AN/A$-22,000,000.00($0.17)-10.59

Celsion has higher revenue and earnings than Tyme Technologies. Tyme Technologies is trading at a lower price-to-earnings ratio than Celsion, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Celsion and Tyme Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celsion-4,315.00%-104.32%-47.65%
Tyme TechnologiesN/A-192.69%-111.68%

Institutional and Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 13.0% of Tyme Technologies shares are owned by institutional investors. 20.5% of Celsion shares are owned by company insiders. Comparatively, 25.5% of Tyme Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Celsion and Tyme Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celsion02002.00
Tyme Technologies00203.00

Celsion presently has a consensus target price of $4.00, suggesting a potential upside of 133.92%. Tyme Technologies has a consensus target price of $9.50, suggesting a potential upside of 427.78%. Given Tyme Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Tyme Technologies is more favorable than Celsion.

Volatility & Risk

Celsion has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Tyme Technologies has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Summary

Celsion beats Tyme Technologies on 7 of the 13 factors compared between the two stocks.


Celsion Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Lannett logo
LCI
Lannett
2.0$6.17-2.1%$255.45 million$545.74 million-8.57Gap Up
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.97-1.3%$251.84 millionN/A-2.82Upcoming Earnings
Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Tricida logo
TCDA
Tricida
1.9$4.74-4.6%$238.16 millionN/A-0.88Gap Up
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$4.84-2.1%$237.04 million$2.72 million-1.22Upcoming Earnings
Gap Down
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
1.2$8.18-0.4%$235.66 million$28.80 million-5.28
Tyme Technologies logo
TYME
Tyme Technologies
1.3$1.80-0.0%$234.77 millionN/A-8.18Increase in Short Interest
Galecto logo
GLTO
Galecto
1.6$9.25-3.7%$233.66 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Down
Cerecor logo
CERC
Cerecor
2.1$3.10-4.2%$232.22 million$6.75 million-10.33Upcoming Earnings
Gap Down
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$4.63-3.2%$232.16 millionN/A-3.76Analyst Upgrade
Analyst Revision
Gap Up
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$3.31-13.0%$224.69 million$1.71 million-7.20Upcoming Earnings
Gap Up
CTI BioPharma logo
CTIC
CTI BioPharma
1.3$2.97-0.3%$224.15 million$3.35 million-4.37Upcoming Earnings
Decrease in Short Interest
News Coverage
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$7.61-1.3%$223.51 million$2.71 million-13.12Increase in Short Interest
News Coverage
Gap Up
Metacrine logo
MTCR
Metacrine
1.7$8.60-3.6%$223.22 millionN/A0.00Upcoming Earnings
Gap Up
OSMT
Osmotica Pharmaceuticals
1.1$3.56-2.2%$222.80 million$240.03 million-3.87Analyst Downgrade
Novan logo
NOVN
Novan
0.9$1.45-5.5%$218.65 million$4.90 million-6.59Analyst Revision
IMV logo
IMV
IMV
0.8$3.21-0.6%$215.36 million$430,000.00-6.98Gap Down
NuCana logo
NCNA
NuCana
1.5$4.38-6.2%$212.41 millionN/A-4.34Earnings Announcement
Decrease in Short Interest
News Coverage
Gap Down
Genprex logo
GNPX
Genprex
1.0$4.90-8.2%$212.06 millionN/A-8.03Decrease in Short Interest
Gap Up
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.4$5.41-4.1%$211.06 million$2.42 million-4.75Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Up
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.5$1.02-7.8%$210.83 million$2.18 million-0.68Increase in Short Interest
Gap Up
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.4$1.38-0.7%$207.45 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Down
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.17-1.6%$206.80 millionN/A-2.54
Milestone Pharmaceuticals logo
MIST
Milestone Pharmaceuticals
1.4$6.91-5.6%$206.08 millionN/A-2.94Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
BIVI
BioVie
1.7$14.78-2.9%$205.68 millionN/A0.00Increase in Short Interest
Gap Down
Enlivex Therapeutics logo
ENLV
Enlivex Therapeutics
1.4$12.99-0.1%$204.72 millionN/A-17.55Analyst Report
Harrow Health logo
HROW
Harrow Health
1.7$7.95-4.9%$204.68 million$51.17 million-99.38Upcoming Earnings
News Coverage
Gap Up
NeuBase Therapeutics logo
NBSE
NeuBase Therapeutics
1.3$8.82-1.6%$204.45 millionN/A-9.80
Aptinyx logo
APTX
Aptinyx
1.4$3.20-0.0%$202.42 million$3.67 million-2.54
PANA
Panacea Acquisition
0.0$10.86-3.3%$200.43 millionN/A0.00High Trading Volume
Gap Up
Concert Pharmaceuticals logo
CNCE
Concert Pharmaceuticals
1.7$6.21-0.8%$199.80 million$1.08 million-2.42Decrease in Short Interest
News Coverage
scPharmaceuticals logo
SCPH
scPharmaceuticals
1.3$7.28-1.5%$198.90 millionN/A-4.49
Abeona Therapeutics logo
ABEO
Abeona Therapeutics
1.6$2.01-3.5%$198.04 million$3 million-1.93Gap Down
Agile Therapeutics logo
AGRX
Agile Therapeutics
1.6$2.23-0.0%$195.41 millionN/A-4.46Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Down
Neptune Wellness Solutions logo
NEPT
Neptune Wellness Solutions
1.3$1.41-0.7%$194.57 million$22.05 million-2.82Gap Up
Calithera Biosciences logo
CALA
Calithera Biosciences
1.7$2.70-0.4%$190.51 million$22.25 million-1.96Upcoming Earnings
Kindred Biosciences logo
KIN
Kindred Biosciences
1.5$4.78-8.2%$188.77 million$4.26 million-6.93News Coverage
Gap Up
Jaguar Health logo
JAGX
Jaguar Health
0.9$1.60-0.6%$188.51 million$5.78 million-0.23Decrease in Short Interest
News Coverage
Gap Down
Strongbridge Biopharma logo
SBBP
Strongbridge Biopharma
1.5$2.78-0.4%$186.94 million$21.71 million-3.05Earnings Announcement
Analyst Report
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$7.72-0.0%$186.93 million$460,000.00-6.49News Coverage
Evofem Biosciences logo
EVFM
Evofem Biosciences
1.5$2.28-43.4%$185.32 millionN/A-1.17Earnings Announcement
High Trading Volume
News Coverage
Gap Down
Tiziana Life Sciences logo
TLSA
Tiziana Life Sciences
1.2$2.87-2.4%$184.31 millionN/A-95.67Gap Up
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$9.00-2.8%$183.51 million$22.90 million-6.77Earnings Announcement
Analyst Revision
News Coverage
Iterum Therapeutics logo
ITRM
Iterum Therapeutics
1.2$1.51-9.9%$182.94 million$40,000.00-0.37Upcoming Earnings
Increase in Short Interest
Gap Up
TLC
Taiwan Liposome
1.2$4.93-0.6%$182.89 million$6.99 million-6.16Upcoming Earnings
OptiNose logo
OPTN
OptiNose
1.6$3.51-0.0%$182.80 million$34.63 million-1.60Earnings Announcement
Increase in Short Interest
Analyst Revision
Medicenna Therapeutics logo
MDNA
Medicenna Therapeutics
0.7$3.50-5.1%$180.51 millionN/A-17.50Increase in Short Interest
News Coverage
Gap Down
Exicure logo
XCUR
Exicure
1.6$2.06-0.5%$180.45 million$1.30 million-7.92Upcoming Earnings
Analyst Report
News Coverage
Gap Down
vTv Therapeutics logo
VTVT
vTv Therapeutics
1.6$2.44-7.4%$180.27 million$2.76 million-5.55Analyst Upgrade
Gap Up
Enochian Biosciences logo
ENOB
Enochian Biosciences
0.3$3.77-4.2%$180.07 millionN/A0.00News Coverage
Gap Down
Chiasma logo
CHMA
Chiasma
1.7$3.08-11.7%$178.04 millionN/A-2.12Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Down
This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.